DexCom’s fourth quarter results reflected ongoing momentum in both product innovation and international expansion. Management attributed the quarter’s performance to the broad rollout of the G7 15-day ...

DexCom Inc. (NASDAQ:DXCM) is one of the best medical technology stocks to invest in. On February 12, DexCom Inc. (NASDAQ:DXCM) shared its Q4 2025 earnings and reported $1.26 billion in quarterly ...

Q4 2025 Earnings Call February 12, 2026 4:30 PM ESTCompany ParticipantsSean Christensen - Vice President of Finance and ...

DexCom (NasdaqGS:DXCM) announced new AI-enabled features for its Stelo glucose monitoring system. The update adds a ...

Wall Street analysts forecast that DexCom (DXCM) will report quarterly earnings of $0.65 per share in its upcoming release, pointing to a year-over-year increase of 44.4%. It is anticipated that ...

Credence Research Inc. has released a new study on the Blood Glucose Monitoring Devices Market. According the report the ...

Analysts expect DexCom to report earnings of $0.6459 per share on revenue of $1.24 billion for the quarter ended December 2025. That would mark a sequential improvement from the third quarter’s $0.61 ...

Insulet Corporation (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its transformative Omnipod 5 Automated Insulin ...

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates, compatible with Abbott and Dexcom continuous glucose sensors ...

DexCom, Inc. DXCM reported fourth-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which beat the Zacks Consensus Estimate of 65 cents by 4.6%. The company reported adjusted earnings of 45 ...

This article discusses the best growth stocks to buy right now.